Start › Szpiczak mnogi › Karolina Północna › Durham
Badania kliniczne dla Szpiczak mnogi w mieście Durham, NC
37 badań dla Szpiczak mnogi szuka uczestników w ośrodkach w mieście Durham i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekrutacjaFaza 3
- Research Site, Chapel Hill · 10 mi dalej
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RekrutacjaFaza 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi dalej
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekrutacjaFaza 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RekrutacjaFaza 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi dalej
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekrutacjaFaza 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi dalej
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekrutacjaFaza 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi dalej
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekrutacjaFaza 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi dalej
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RekrutacjaFaza 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi dalej
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RekrutacjaFaza 1/2
- GSK Investigational Site, Chapel Hill · 10 mi dalej
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekrutacjaFaza 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekrutacjaFaza 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekrutacjaFaza 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi dalej
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Rekrutacja
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi dalej
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RekrutacjaFaza 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RekrutacjaFaza 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi dalej
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekrutacjaFaza 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi dalej
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RekrutacjaFaza 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi dalej
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RekrutacjaFaza 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi dalej
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
RekrutacjaFaza 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi dalej
Registry of Older Patients With Cancer
RekrutacjaBadanie obserwacyjne
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi dalej
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekrutacjaFaza 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RekrutacjaFaza 2
- University of North Carolina, Chapel Hill · 10 mi dalej
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RekrutacjaFaza 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi dalej
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RekrutacjaFaza 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi dalej
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekrutacjaFaza 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi dalej
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekrutacjaFaza 1
- University of North Carolina, Chapel Hill · 10 mi dalej
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RekrutacjaFaza 1
- University of North Carolina, Chapel Hill · 10 mi dalej
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekrutacjaFaza 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi dalej
Registry for Adults With Plasma Cell Disorders (PCD's)
RekrutacjaBadanie obserwacyjne
- North Carolina Cancer Hospital, Chapel Hill · 10 mi dalej
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RekrutacjaBadanie obserwacyjne
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi dalej
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekrutacjaFaza 1
- Duke University Health System (DUHS), Durham
Badania dla Szpiczak mnogi w innych miastach
- New York City, NY60 badań
- Boston, MA42 badań
- Atlanta, GA41 badań
- Houston, TX38 badań
- Nashville, TN32 badań
- Denver, CO27 badań
- Rochester, MN24 badań
- St. Louis, MO24 badań
- Columbus, OH24 badań
- Baldwin Park, CA23 badań
- Chicago, IL22 badań
- Seattle, WA22 badań
Inne badania w mieście Durham
- Rak piersi63 badań
- Nowotwory (wszystkie typy)58 badań
- Niedrobnokomórkowy rak płuca39 badań
- Nowotwór przerzutowy33 badań
- Ostra białaczka szpikowa33 badań
- Rak płuc32 badań
- Rak prostaty32 badań
- Rak jelita grubego i odbytnicy28 badań
- Przewlekła białaczka limfocytowa27 badań
- Rak jajnika27 badań
- Niewydolność serca26 badań
- Rak trzustki24 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.